Stocktoria
BNB PLUS CORP. BNBX
BNB PLUS CORP. (BNBX) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.1M at a -709.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BNBX | BNB PLUS CORP. | 2/9 | — | — | — |
| AIDX | 20/20 Biolabs, Inc. | 4/9 | — | — | — |
| NEO | NEOGENOMICS INC | 5/9 | 1.46 | — | +10.1% |
| ULS | UL Solutions Inc. | 6/9 | 3.1 | 60.8 | +6.4% |
| GOOG | Alphabet Inc. | 5/9 | 6.79 | 31.1 | +15.1% |
| MSFT | MICROSOFT CORP | 6/9 | 4.49 | 20.7 | +17.8% |
| META | Meta Platforms, Inc. | 4/9 | 5.34 | 23.1 | +22.2% |
About BNB PLUS CORP.
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP, and LineaIVT, as well as the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. BNB Plus Corp. was formerly known as Applied DNA Sciences, Inc. and changed its name to BNB Plus Corp. in November 2025. The company was founded in 1983 and is based in Stony Brook, New York.
FAQ
Is BNBX financially healthy?
BNB PLUS CORP.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does BNBX pay a dividend?
No, BNB PLUS CORP. does not currently pay a dividend.
How profitable is BNBX?
In FY2025, BNB PLUS CORP. had a net margin of -709.5% and a return on equity of -657.8%.
Is BNBX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BNB PLUS CORP.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.